NDAA yields 2.71% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, NDAA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NDAA + ABBV for your $10,000?
NDAA aims to maximize return opportunities by adapting investments to market shifts through a proprietary, data-driven, 360-degree approach. This serves as a broad asset allocation guide for a selection of passively managed ETFs, integrating data from four key pillars: macroeconomic, fundamental, technical, and sentiment analyses. The strategy allows for a holistic view of market conditions and dynamically shifts assets across equities, fixed income, commodities, and money markets. The raw data inputs utilized are sourced from market data providers such as Bloomberg, S&P, MSCI, and others. Typically, the fund targets a 60/40 allocation to equities and bonds, with adjustments made based on prevailing market conditions. Note that the portfolio may fully switch to either equities or bonds. Holdings will generally consist of 5 to 20 underlying ETFs and may also include cash or cash equivalents. On a monthly basis, the fund reviews its holdings and may experience a high portfolio turnover rate.
Full NDAA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.